Table 2.

Time-to-Event Outcomes

	6-month CDW	New attack	New MRI activity
Univariate analysis
Pretreatment stop sNfL	0.86 [0.41–1.81]; p = 0.697	0.82 [0.38–1.77]; p = 0.609	0.59 [0.29–1.18]; p = 0.135
Posttreatment stop sNfL	1.42 [0.73–2.79]; p = 0.306	0.82 [0.39–1.75]; p = 0.609	1.00 [0.51–1.95]; p = 0.995
Percent change in sNfL	1.44 [1.04–1.99]; p = 0.026	1.16 [0.73–1.83]; p = 0.527	1.56 [1.15–2.11]; p = 0.004
Pretreatment stop sGFAP	0.85 [0.37–1.97]; p = 0.704	0.96 [0.39–2.33]; p = 0.924	0.49 [0.22–1.10]; p = 0.085
Posttreatment stop sGFAP	0.89 [0.34–2.33]; p = 0.815	0.87 [0.32–2.39]; p = 0.789	0.77 [0.31–1.92]; p = 0.574
Percent change in sGFAP	1.94 [0.45–8.34]; p = 0.374	1.23 [0.24–6.28]; p = 0.801	5.68 [1.68–19.2]; p = 0.005
Multivariable analysisa
Pretreatment stop sNfL	1.32 [0.56–3.13]; p = 0.524	1.49 [0.55–4.07]; p = 0.433	2.09 [0.86–5.07]; p = 0.103
Posttreatment stop sNfL	2.80 [1.36–5.76]; p = 0.005	1.41 [0.55–3.62]; p = 0.475	3.09 [1.42–6.70]; p = 0.004
Percent change in sNfL	1.42 [1.03–1.96]; p = 0.033	1.12 [0.70–1.80]; p = 0.634	1.36 [0.97–1.89]; p = 0.071
Pretreatment stop sGFAP	0.96 [0.34–2.74]; p = 0.940	2.87 [0.84–9.77]; p = 0.093	1.04 [0.39–2.76]; p = 0.934
Posttreatment stop sGFAP	1.27 [0.39–4.08]; p = 0.694	2.40 [0.66–8.76]; p = 0.185	2.45 [0.80–7.49]; p = 0.117
Percent change in sGFAP	3.48 [0.65–18.6]; p = 0.144	0.82 [0.16–4.25]; p = 0.809	4.88 [1.28–18.6]; p = 0.021

Abbreviations: CDW = confirmed disability worsening; EDSS = Expanded Disability Status Scale; sGFAP = serum glial fibrillary acidic protein; sNfL = serum neurofilament light chain.

Data shown as hazard ratio [95% CI]; p value.

Pretreatment and posttreatment stop biomarker levels were log transformed.

Percent change was calculated from nontransformed levels: reported hazard ratios represent a doubling or 100% increase.

^aAdjusted for covariates: age, disease duration, EDSS, duration from last attack (at treatment stop date), and batch effect.